Darel Martinez Bedoya

Darel Martinez Bedoya

Auto-generated profile, based on publicly available information

Darel Martinez Bedoya

Brain Tumor and Immune Cell Engineering Laboratory, AGORA Cancer Research Center, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
AGAli Ghasemi
Ali Ghasemi
AMAmaia Martinez-Usatorre
Amaia Martinez-Usatorre
LLLuqing Li
Luqing Li
MHMehdi Hicham
Mehdi Hicham
AGAlan Guichard
Alan Guichard
MPMichele De Palma
Michele De Palma
Dendritic cells (DCs) are antigen-presenting myeloid cells that regulate T cell activation, trafficking and function. Monocyte-derived DCs pulsed with tumor antigens have been tested extensively for therapeutic vaccination in cancer, with mixed clinical results. Here, we present a cell-therapy platform based on mouse or human DC progenitors (DCPs) engineered to produce two immunostimulatory cytokines, IL-12 and FLT3L. Cytokine-armed DCPs differentiated into conventional type-I DCs (cDC1) and suppressed tumor growth, including melanoma and autochthonous liver models, without the need for antigen loading or myeloablative host conditioning. Tumor response involved synergy between IL-12 and FLT3L and was associated with natural killer and T cell infiltration and activation, M1-like macrophage programming and ischemic tumor necrosis. Antitumor immunity was dependent on endogenous cDC1 expansion and interferon-γ signaling but did not require CD8+ T cell cytotoxicity. Cytokine-armed DCPs synergized effectively with anti-GD2 chimeric-antigen receptor (CAR) T cells in eradicating intracranial gliomas in mice, illustrating their potential in combination therapies.

13 September 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DBDarel Martinez Bedoya
Darel Martinez Bedoya
EMEliana Marinari
Eliana Marinari
SDSuzel Davanture
Suzel Davanture
LCLuis Castillo Cantero
Luis Castillo Cantero
SESarah Erraiss
Sarah Erraiss
DMDenis Migliorini
Denis Migliorini
The great success of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with B-cell malignancies has prompted its translation to solid tumors. In the case of glioblastoma (GBM), clinical trials have shown modest efficacy, but efforts to develop more effective anti-GBM CAR T cells are ongoing. In this study, we selected protein tyrosine phosphatase receptor type Z (PTPRZ1) as a target for GBM treatment. We isolated six anti-human PTPRZ1 single-chain variable fragments from a human phage display library and produced second-generation CAR T cells in an RNA format. Patient-derived GBM PTPRZ1–knockin cell lines were used to select the CAR construct that showed high cytotoxicity while consistently displaying high CAR expression (471_28z). CAR T cells incorporating 471_28z were able to release IFNγ, IL2, TNFα, granzyme B, IL17A, IL6, and soluble FasL and displayed low tonic signaling. Additionally, they maintained an effector memory phenotype after in vitro killing. In addition, 471_28z CAR T cells displayed strong bystander killing against PTPRZ1-negative cell lines after preactivation by PTPRZ1-positive tumor cells but did not kill antigen-negative nontumor cells. In an orthotopic xenograft tumor model using NOD/SCIDγ mice, a single dose of anti-PTPRZ1 CAR T cells significantly delayed tumor growth. Taken together, these results validate PTPRZ1 as a GBM target and prompt the clinical translation of anti-PTPRZ1 CAR T cells.

1 January 2022 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
DFDasha Fuentes
Dasha Fuentes
Alejandro Cabezas-CruzAlejandro Cabezas-Cruz
Alejandro Cabezas-Cruz
CMCirce Mesa
Circe Mesa
TCTania Carmenate
Tania Carmenate
DMDarel Martínez
Darel Martínez
RPRolando Pérez-vela
Rolando Pérez-vela
Fuentes D, et al. J Breast Cancer. 2022 Apr;25:e18. https://doi.org/10.4048/jbc.2022.25.e18

17 June 2026
Verified
Other
Open access
DBDarel Martinez Bedoya
Darel Martinez Bedoya
EMEliana Marinari
Eliana Marinari
SDSuzel Davanture
Suzel Davanture
LCLuis Castillo Cantero
Luis Castillo Cantero
SESarah Erraiss
Sarah Erraiss
DMDenis Migliorini
Denis Migliorini
Anti-PTPRZ1 CAR-T cell effector function after incubation with the Ge1302_PTPRZ1-KI cells

17 June 2026
Verified
Other
Open access
DBDarel Martinez Bedoya
Darel Martinez Bedoya
EMEliana Marinari
Eliana Marinari
SDSuzel Davanture
Suzel Davanture
LCLuis Castillo Cantero
Luis Castillo Cantero
SESarah Erraiss
Sarah Erraiss
DMDenis Migliorini
Denis Migliorini
In vivo anti-tumor activity of anti-PTPRZ1 CAR-T cells

3 December 2024
Verified
Other
Open access
DBDarel Martinez Bedoya
Darel Martinez Bedoya
EMEliana Marinari
Eliana Marinari
SDSuzel Davanture
Suzel Davanture
LCLuis Castillo Cantero
Luis Castillo Cantero
SESarah Erraiss
Sarah Erraiss
DMDenis Migliorini
Denis Migliorini
Bystander killing by anti-PTPRZ1 CAR-T cells using additional tumor cell lines and scFv